Results 151 to 160 of about 1,201,054 (248)

Quantifying outer membrane permeability to β-lactam antibiotics using outer membrane vesicles that protect antibiotic-susceptible bacteria. [PDF]

Nat Commun
Razew A, Herail Q, Ayala I, Guissouma M, Arthur M, Simorre JP.   +5 more
europepmc   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Structural Interactions of β-Lactam Antibiotics with Mammalian Serum Albumins. [PDF]

Int J Mol Sci
Duszynski K, Sekula B, Talaj J, Bujacz A.   +3 more
europepmc   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treat <i>Pseudomonas aeruginosa</i> clinical isolates. [PDF]

JAC Antimicrob Resist
Mystakelis H, Shields RK, Mathers AJ, Bergman Y, Munita JM, Cosgrove SE, Simner PJ, Tamma PD.   +7 more
europepmc   +1 more source

Carriage of antimicrobial‐resistant E. coli in urban stray cats (Felis catus)

Australian Veterinary Journal, EarlyView.
Antimicrobial resistance (AMR) in Escherichia coli is a growing concern in both human and veterinary medicine, driven by the inappropriate use of antimicrobials. Companion animals may act as community reservoirs and sentinels for antimicrobial‐resistant bacteria due to their close contact with humans and other animals.
JS Kuan, S Mukerji, D Hampson, S Abraham
wiley   +1 more source

The innate immune protein calprotectin ablates the bactericidal activity of β-lactam antibiotics. [PDF]

Proc Natl Acad Sci U S A
Velez AZ, Radin JN, Kennedy EN, Parsons JB, Tong HM, Jung E, Alam E, Radlinski LC, Wagner NJ, Fowler VG, Rowe SE, Kehl-Fie T, Conlon BP.   +12 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Natural Products as Potentiators of β-Lactam Antibiotics: A Review of Mechanisms, Advances, and Future Directions. [PDF]

Antioxidants (Basel)
Yang W, Fan S, Luo J, Zhou Y, Dai X, Huang J, Wang L, Wang X.   +7 more
europepmc   +1 more source

Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket

British Journal of Pharmacology, EarlyView.
NLRP3 is a promising inflammatory target, but existing inhibitors lack diversity and brain penetrance, and none are approved. Using chemoproteomics, we discovered a novel series that binds to Cys463 in a previously uncharacterized pocket. Compounds showed nanomolar potency, brain exposure, and in vivo suppression of IL‐1β, supporting neuroinflammatory ...
Donald C. Rogness, Evelyn P. Sievert, Vincent F. Vartabedian, Steffen M. Bernard, Erick Aitchison, William Tao, Mikaela Lindvall, Jing Qian, Christie L. Eissler, Brian E. Nordin, Benjamin D. Horning, Cian Kingston, Kelsey N. Lamb, Joshua C. Bell, Bingwen Lu, Jonathan Pollock, Jun Shi, Roli Khattri, David S. Weinstein, Matthew P. Patricelli, Brian N. Cook, Gabriel M. Simon   +21 more
wiley   +1 more source